Product Code: GVR-4-68040-192-4
Microbial Identification Market Growth & Trends:
The global microbial identification market size is anticipated to reach USD 7.95 billion by 2030 and is anticipated to expand at a CAGR of 11.8% during the forecast period, according to a new report by Grand View Research, Inc. The rising prevalence of infectious diseases and the need for rapid and accurate identification of microbial pathogens have created a strong demand for advanced identification technologies. This is particularly marked in healthcare settings, where on time diagnosis and treatment of infections are critical for patient outcomes. According to Australian Institute of Health and Welfare, July 2022 statistics, in 2020-21, there were around 3,24,000 hospitalizations for infectious diseases, 94% of which were non-notifiable. In addition, the raising awareness of food safety and the need to control foodborne pathogens have led to the adoption of microbial identification techniques in the food industry, further driving the market growth.
Moreover, advancements in technology such as automation and real time analysis play a pivotal role in the expansion of this market. Innovations such as next-generation sequencing, mass spectrometry, and automated microbial identification systems have enhanced the speed and accuracy of microbial identification, making them more accessible and reliable. For instance, in April 2023, Bruker introduced new MBT Mycobacteria IVD Kit offers best-in-class diagnostic solutions and user-friendly for infection diagnostics laboratories and routine clinical microbiology. These technological advancements have attracted the attention of both clinical laboratories and research institutions, driving market growth.
The regulatory environment has also had an impact on the growth of the microbial identification industry. To maintain product safety and compliance, numerous industries, including pharmaceuticals, healthcare, and food, have implemented stringent rules and quality control standards, necessitating the employment of accurate identification procedures. To meet regulatory standards, has boosted the introduction of microbiological identification solutions.
However, the cost of microbiological identification tools and technology can be a considerable obstacle. High initial capital investment and continuous operational costs can dissuade healthcare facilities and laboratories from adopting this advanced equipment, particularly in resource-constrained situations. Thus, the cost aspect may limit the market's reach, particularly in poor countries.
Microbial Identification Market Report Highlights:
- The consumables segment dominated the product & services segment with a revenue share of 36.51% in 2023, owing to the rising demand for animal-free cell-based therapies
- The software & services segment is expected to grow at the fastest CAGR over the forecast period due to the advancements in technology which focuses on development of specialized software that can better support the unique needs of different genetic pool of microorganisms for better microbial identification
- The PCR segment dominated the technology segment with a revenue share in 2023, owing to the technological advancement in the field of microbial identification
- The genotypic segment dominated the method segment with a revenue share in 2023 and expected to maintain the same over the forecast period
- The clinical diagnostics segment dominated the application segment with a revenue share in 2023, due to the growing number of research & diagnostic activities for various drug and vaccine development
- Based on end use, the hospitals & diagnostic laboratories segment dominated the market in 2023. On the other hand, pharmaceutical & biotechnology companies is expected to witness the fastest growth over the forecast period
- The North America region dominated the market owing to factors such as the presence of key market players rising adaptation of advance technology in identification and rising research and development in various fields. Moreover, the growing prevalence of infectious diseases is further anticipated to boost the market for microbial identification in the region over the forecast period
- Asia Pacific is expected to register the fastest growth over the forecast period due to several companies expanding their presence in Asia Pacific countries like Japan and India
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.1.1. Product & Services
- 1.1.2. Technology
- 1.1.3. Method
- 1.1.4. Application
- 1.1.5. End-use
- 1.2. Regional Scope
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Primary Research
- 1.6. Information or Data Analysis:
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Validation
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. List of Abbreviations
- 1.11. Objective
- 1.11.1. Objective 1
- 1.11.2. Objective 2
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Rising prevalence of infectious diseases
- 3.2.1.2. Technological advancements
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. High cost of automated microbial identification systems
- 3.3. Industry Analysis Tools
- 3.3.1. Porter's Five Forces Analysis
- 3.3.2. PESTEL Analysis
- 3.3.3. COVID-19 Impact Analysis
Chapter 4. Product & Services Business Analysis
- 4.1. Microbial Identification Market: Product & Services Movement Analysis
- 4.2. Instrument
- 4.2.1. Instrument market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.2.2. Mass Spectrometers
- 4.2.2.1. Maa spectrometers market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.2.3. PCR Systems
- 4.2.3.1. PCR systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.2.4. Microarrays
- 4.2.4.1. Microarrays market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.2.5. Others
- 4.2.5.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.3. Consumables
- 4.3.1. Consumables market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.3.2. Reagents & Kits
- 4.3.2.1. Reagents & kits market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.3.3. Plates & Media
- 4.3.3.1. Plates & media market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.4. Software & Services
- 4.4.1. Software & services market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.4.2. Identification Services
- 4.4.2.1. Identification services market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.4.3. Culture Collection Services
- 4.4.3.1. Culture collection services market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.4.4. Assay Validation Services
- 4.4.4.1. Assay validation services market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 5. Technology Business Analysis
- 5.1. Microbial Identification Market: Technology Movement Analysis
- 5.2. Mass Spectrometry
- 5.2.1. Mass spectrometry market estimates and forecasts, 2018 - 2030 (USD Million)
- 5.3. PCR
- 5.3.1. PCR market estimates and forecasts, 2018 - 2030 (USD Million)
- 5.4. Microarrays
- 5.4.1. Microarrays market estimates and forecasts, 2018 - 2030 (USD Million)
- 5.5. Next Generation Sequencing
- 5.5.1. Next generation sequencing market estimates and forecasts, 2018 - 2030 (USD Million)
- 5.6. Others
- 5.6.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 6. Method Business Analysis
- 6.1. Microbial Identification Market: Method Movement Analysis
- 6.2. Phenotypic Methods
- 6.2.1. Phenotypic methods market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.3. Genotypic Methods
- 6.3.1. Genotypic methods market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.4. Proteotypic Methods
- 6.4.1. Proteotypic methods market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 7. Application Business Analysis
- 7.1. Microbial Identification Market: Application Movement Analysis
- 7.2. Clinical Diagnostics
- 7.2.1. Clinical diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.3. Pharmaceuticals
- 7.3.1. Pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.4. Food & Beverage Testing
- 7.4.1. Food & beverage testing market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.5. Environmental Application
- 7.5.1. Environmental application market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.6. Others
- 7.6.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 8. End-use Group Business Analysis
- 8.1. Microbial Identification Market: End-use Movement Analysis
- 8.2. Pharmaceutical & Biotechnology Companies
- 8.2.1. Pharmaceutical & biotechnology companies market estimates and forecasts, 2018 - 2030 (USD Million)
- 8.3. Hospitals & Diagnostic Laboratories
- 8.3.1. Hospitals & diagnostic laboratories market estimates and forecasts, 2018 - 2030 (USD Million)
- 8.4. Food Testing Laboratories
- 8.4.1. Food testing laboratories market estimates and forecasts, 2018 - 2030 (USD Million)
- 8.5. Others
- 8.5.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 9. Regional Business Analysis
- 9.1. Microbial Identification Share By Region, 2023 & 2030
- 9.2. North America
- 9.2.1. North America Microbial Identification, 2018 - 2030 (USD Million)
- 9.2.2. U.S.
- 9.2.2.1. Key Country Dynamics
- 9.2.2.2. Competitive Scenario
- 9.2.2.3. Regulatory Framework
- 9.2.2.4. U.S. Microbial Identification, 2018 - 2030 (USD Million)
- 9.2.3. Canada
- 9.2.3.1. Key Country Dynamics
- 9.2.3.2. Competitive Scenario
- 9.2.3.3. Regulatory Framework
- 9.2.3.4. Canada Microbial Identification, 2018 - 2030 (USD Million)
- 9.3. Europe
- 9.3.1. Europe Microbial Identification, 2018 - 2030 (USD Million)
- 9.3.2. UK
- 9.3.2.1. Key Country Dynamics
- 9.3.2.2. Competitive Scenario
- 9.3.2.3. Regulatory Framework
- 9.3.2.4. UK Microbial Identification, 2018 - 2030 (USD Million)
- 9.3.3. Germany
- 9.3.3.1. Key Country Dynamics
- 9.3.3.2. Competitive Scenario
- 9.3.3.3. Regulatory Framework
- 9.3.3.4. Germany Microbial Identification, 2018 - 2030 (USD Million)
- 9.3.4. France
- 9.3.4.1. Key Country Dynamics
- 9.3.4.2. Competitive Scenario
- 9.3.4.3. Regulatory Framework
- 9.3.4.4. France Microbial Identification, 2018 - 2030 (USD Million)
- 9.3.5. Italy
- 9.3.5.1. Key Country Dynamics
- 9.3.5.2. Competitive Scenario
- 9.3.5.3. Regulatory Framework
- 9.3.5.4. Italy Microbial Identification, 2018 - 2030 (USD Million)
- 9.3.6. Spain
- 9.3.6.1. Key Country Dynamics
- 9.3.6.2. Competitive Scenario
- 9.3.6.3. Regulatory Framework
- 9.3.6.4. Spain Microbial Identification, 2018 - 2030 (USD Million)
- 9.3.7. Denmark
- 9.3.7.1. Key Country Dynamics
- 9.3.7.2. Competitive Scenario
- 9.3.7.3. Regulatory Framework
- 9.3.7.4. Denmark Microbial Identification, 2018 - 2030 (USD Million)
- 9.3.8. Sweden
- 9.3.8.1. Key Country Dynamics
- 9.3.8.2. Competitive Scenario
- 9.3.8.3. Regulatory Framework
- 9.3.8.4. Sweden Microbial Identification, 2018 - 2030 (USD Million)
- 9.3.9. Norway
- 9.3.9.1. Key Country Dynamics
- 9.3.9.2. Competitive Scenario
- 9.3.9.3. Regulatory Framework
- 9.3.9.4. Norway Microbial Identification, 2018 - 2030 (USD Million)
- 9.4. Asia Pacific
- 9.4.1. Asia Pacific Microbial Identification, 2018 - 2030 (USD Million)
- 9.4.2. Japan
- 9.4.2.1. Key Country Dynamics
- 9.4.2.2. Competitive Scenario
- 9.4.2.3. Regulatory Framework
- 9.4.2.4. Japan Microbial Identification, 2018 - 2030 (USD Million)
- 9.4.3. China
- 9.4.3.1. Key Country Dynamics
- 9.4.3.2. Competitive Scenario
- 9.4.3.3. Regulatory Framework
- 9.4.3.4. China Microbial Identification, 2018 - 2030 (USD Million)
- 9.4.4. India
- 9.4.4.1. Key Country Dynamics
- 9.4.4.2. Competitive Scenario
- 9.4.4.3. Regulatory Framework
- 9.4.4.4. India Microbial Identification, 2018 - 2030 (USD Million)
- 9.4.5. Australia
- 9.4.5.1. Key Country Dynamics
- 9.4.5.2. Competitive Scenario
- 9.4.5.3. Regulatory Framework
- 9.4.5.4. Australia Microbial Identification, 2018 - 2030 (USD Million)
- 9.4.6. Thailand
- 9.4.6.1. Key Country Dynamics
- 9.4.6.2. Competitive Scenario
- 9.4.6.3. Regulatory Framework
- 9.4.6.4. Thailand Microbial Identification, 2018 - 2030 (USD Million)
- 9.4.7. South Korea
- 9.4.7.1. Key Country Dynamics
- 9.4.7.2. Competitive Scenario
- 9.4.7.3. Regulatory Framework
- 9.4.7.4. South Korea Microbial Identification, 2018 - 2030 (USD Million)
- 9.5. Latin America
- 9.5.1. Latin America Microbial Identification, 2018 - 2030 (USD Million)
- 9.5.2. Brazil
- 9.5.2.1. Key Country Dynamics
- 9.5.2.2. Competitive Scenario
- 9.5.2.3. Regulatory Framework
- 9.5.2.4. Brazil Microbial Identification, 2018 - 2030 (USD Million)
- 9.5.3. Mexico
- 9.5.3.1. Key Country Dynamics
- 9.5.3.2. Competitive Scenario
- 9.5.3.3. Regulatory Framework
- 9.5.3.4. Mexico Microbial Identification, 2018 - 2030 (USD Million)
- 9.5.4. Argentina
- 9.5.4.1. Key Country Dynamics
- 9.5.4.2. Competitive Scenario
- 9.5.4.3. Regulatory Framework
- 9.5.4.4. Argentina Microbial Identification, 2018 - 2030 (USD Million)
- 9.6. MEA
- 9.6.1. MEA Microbial Identification, 2018 - 2030 (USD Million)
- 9.6.2. South Africa
- 9.6.2.1. Key Country Dynamics
- 9.6.2.2. Competitive Scenario
- 9.6.2.3. Regulatory Framework
- 9.6.2.4. South Africa Microbial Identification, 2018 - 2030 (USD Million)
- 9.6.3. Saudi Arabia
- 9.6.3.1. Key Country Dynamics
- 9.6.3.2. Competitive Scenario
- 9.6.3.3. Regulatory Framework
- 9.6.3.4. Saudi Arabia Microbial Identification, 2018 - 2030 (USD Million)
- 9.6.4. UAE
- 9.6.4.1. Key Country Dynamics
- 9.6.4.2. Competitive Scenario
- 9.6.4.3. Regulatory Framework
- 9.6.4.4. UAE Microbial Identification, 2018 - 2030 (USD Million)
- 9.6.5. Kuwait
- 9.6.5.1. Key Country Dynamics
- 9.6.5.2. Competitive Scenario
- 9.6.5.3. Regulatory Framework
- 9.6.5.4. Kuwait Microbial Identification, 2018 - 2030 (USD Million)
Chapter 10. Competitive Landscape
- 10.1. Company Categorization
- 10.2. Strategy Mapping
- 10.3. Company Market Position Analysis, 2023
- 10.4. Company Profiles/Listing
- 10.4.1. bioMerieux SA
- 10.4.1.1. Overview
- 10.4.1.2. Financial Performance
- 10.4.1.3. Product Benchmarking
- 10.4.1.4. Strategic Initiatives
- 10.4.2. Becton, Dickinson and Company
- 10.4.2.1. Overview
- 10.4.2.2. Financial Performance
- 10.4.2.3. Product Benchmarking
- 10.4.2.4. Strategic Initiatives
- 10.4.3. Thermo Fisher Scientific Inc.
- 10.4.3.1. Overview F
- 10.4.3.2. Financial Performance
- 10.4.3.3. Product Benchmarking
- 10.4.3.4. Strategic Initiatives
- 10.4.4. Bruker Corporation
- 10.4.4.1. Overview
- 10.4.4.2. Financial Performance
- 10.4.4.3. Product Benchmarking
- 10.4.4.4. Strategic Initiatives
- 10.4.5. Beckman Coulter
- 10.4.5.1. Overview
- 10.4.5.2. Product Benchmarking
- 10.4.5.3. Strategic Initiatives
- 10.4.6. Qiagen N.V.
- 10.4.6.1. Overview
- 10.4.6.2. Financial Performance
- 10.4.6.3. Product Benchmarking
- 10.4.6.4. Strategic Initiatives
- 10.4.7. Charles River Laboratories
- 10.4.7.1. Overview
- 10.4.7.2. Financial Performance
- 10.4.7.3. Product Benchmarking
- 10.4.7.4. Strategic Initiatives
- 10.4.8. Wickham Micro Limited
- 10.4.8.1. Overview
- 10.4.8.2. Product Benchmarking
- 10.4.8.3. Strategic Initiatives
- 10.4.9. VWR International LLC. (Avantor Inc.)
- 10.4.9.1. Overview
- 10.4.9.2. Product Benchmarking
- 10.4.9.3. Strategic Initiatives
- 10.4.10. Shimadzu Corporation
- 10.4.10.1. Overview
- 10.4.10.2. Financial Performance
- 10.4.10.3. Product Benchmarking
- 10.4.10.4. Strategic Initiatives
- 10.4.11. Merck KGaA
- 10.4.11.1. Overview
- 10.4.11.2. Financial Performance
- 10.4.11.3. Product Benchmarking
- 10.4.11.4. Strategic Initiatives
- 10.4.12. Eurofins Scientific SE
- 10.4.12.1. Overview
- 10.4.12.2. Financial Performance
- 10.4.12.3. Product Benchmarking
- 10.4.12.4. Strategic Initiatives
- 10.4.13. Biolog Inc.
- 10.4.13.1. Overview
- 10.4.13.2. Product Benchmarking
- 10.4.13.3. Strategic Initiatives